Navigation Links
AMT Announces Positive Interim Clinical Data on its Lead Product AMT-011
Date:5/29/2008

AMSTERDAM, May 30 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that positive interim data from its pivotal clinical trial with AMT's lead product Glybera(R) (AMT-011) were presented by the Principal Investigator, professor Daniel Gaudet, at the American Society of Gene Therapy Annual Meeting in Boston on May 29th. These data confirm the outcome of a previous study conducted in The Netherlands, demonstrating safety and efficacy of Glybera(R) for lipoprotein-lipase deficiency, a disease also known as Hyperlipoproteinemia (HPL) type I. Currently, there is no effective treatment or cure for this seriously debilitating and potentially lethal disease.

Study data

Glybera(R) is a gene therapy product that corrects the genetic defect in lipoprotein-lipase (LPL) deficient patients. LPL is normally produced in muscle tissue and is needed to break down the large fat-carrying particles that circulate in the blood after each meal. As a result, LPL-deficient patients have very high fat (triglyceride) levels in their blood which may lead to recurrent episodes of pancreatitis, insulin resistance, and fat accumulations in skin as well as liver and retina.

In the pivotal study conducted in Quebec (Canada), patients with LPL-deficiency were first enrolled in an observation study and subsequently treated in a study in which there are two different dose groups. All patients showed very high fat levels in the observation study and had experienced (recurrent) pancreatitis episodes prior to treatment. To date 6 patients have been treated with the lower dose and 7 with the higher dose.

Professor Gaudet presented data on the first 10 patients, of which 6 were in the lower dose group and 4 were in the higher dose group. The data showed that treatment was well tolerated. Fat concentrations were reduced after treatment in all patients, with one exception. In all patients
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015  MiMedx Group, Inc. (NASDAQ: ... human amniotic tissue and patent-protected processes to develop ... Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic ... corrected the multiple inaccuracies in the press release ... the recent rulings from the Patent Trial and ...
(Date:8/27/2015)... 27, 2015 According to a ... Type (Integrated, Standalone), by Deployment Mode (Web based, On-Premise, ... Healthcare Service Providers), by Component - Global Trends & ... is estimated at $501.1 Million 2014, and is projected ... of 7.6% from 2014 to 2019. ...
(Date:8/27/2015)... , Aug. 27, 2015  Mytrus, a technology and services ... platform for electronic informed consent has received approval for ... Service (NHS). It is the first time e-Consent technology ... England . Mytrus was also ... in a clinical trial by the U.S. Food and ...
Breaking Medicine Technology:MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4Radiology Information Systems Market Worth $722.7 Million by 2019 2Radiology Information Systems Market Worth $722.7 Million by 2019 3Radiology Information Systems Market Worth $722.7 Million by 2019 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 2Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 3Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 4Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 5Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 6Britain's National Health Service Approves The Use Of Mytrus Technology For Electronic Informed Consent In Clinical Trials 7
... March 6, 2012 Biospace Lab S.A. ... College London will collaborate on the development of novel ... of the Biospace Lab PhotonIMAGER™ Optima pre-clinical imaging platform. ... Dr Mark Lythgoe, and molecular probes, Dr Martin Pule, ...
... GP Strategies Corporation (NYSE: GPX ), ... sales and technical training, e-Learning solutions, management consulting and ... CFO Sharon Esposito-Mayer will speak at the ROTH Capital ... 3:30 p.m. PT. The conference will be held at ...
Cached Medicine Technology:Biospace Lab and the Centre for Advanced Biomedical Imaging at University College London to Collaborate on Development of Novel Real-Time in Vivo Optical Imaging Technologies 2
(Date:8/28/2015)... ... August 28, 2015 , ... The newest therapy to receive orphan drug ... use any time soon, according to educational website Surviving Mesothelioma. Click here to ... drug designation for mesothelioma last week from the FDA, will now head into Phase ...
(Date:8/28/2015)... ... August 28, 2015 , ... United ... to welcome TJS Insurance Group as its newest Partner Firm. Founded in 1924 ... and keeps them focused on their goals. Within the past 10 years, TJS ...
(Date:8/28/2015)... ... August 28, 2015 , ... External Counterpulsation, also known as ECP ... now selling External Counterpulsation (EECP or ECP) machines with a full clinic licence to ... in business since 2007 helping people prevent and reverse heart disease through ...
(Date:8/28/2015)... ... ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... in order to ease the stress on the atmosphere, and lessen the number and ... the real cause of global warming and urges them to look into his studies ...
(Date:8/28/2015)... ... 2015 , ... Inc. magazine today ranked PREVENT Life Safety No. ... fastest-growing private companies. The list was unveiled online at Inc.com and is the most ... three years, PREVENT ranks higher on the list than any other company in their ...
Breaking Medicine News(10 mins):Health News:Surviving Mesothelioma Puts New Orphan Drug into Perspective in New Article 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:Buy New External Counterpulsation (EECP or ECP) With Heart Fit Clinic 2Health News:Wake Up and Smell the Sick Atmosphere Says Yisrayl Hawkins in New Article This Week 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
... Surgical Company (Nasdaq: STAA ), a developer, manufacturer ... announced the completion of a registered direct offering of 4,255,319 ... per share, which was the closing market price on June ... million because the Company did not use an underwriter for ...
... & rescue manager won contest to clone beloved pet Trakr, hero ... Can you clone a hero? ... rescue dog and 9-11 hero, Trakr, will receive five answers to ... California biotech company that is offering the first commercial dog cloning ...
... ... that it is taking sign-ups for this year,s annual subtle energies and healing conference. ... is called "Sacred Synthesis: Science with Heart". , ... Denver, CO (PRWEB) June 17, 2009 -- ISSSEEM (International ...
... ... of the clinical study that was performed using the Bariatric Advantage High Protein Meal ... Obesity (ECO). , ... Amsterdam, Holland (Vocus) June 17, 2009 -- Bariatric Advantage presented the results of the ...
... ... Remote Control 4.0. It allows help desk staff to administer and remotely control ... easy to find computers With its unique search engine. It can find the ... http://www.intelliadmin.com/blog/index.php/2009/06/remote-control-40-beta-rc4-and-usb-disabler-pro/ , ...
... ... of the University of Oklahoma, OU Physicians has established a standard of efficient patient centered ... facility was designed to consolidate the private practices for physicians teaching at the University of ... ...
Cached Medicine News:Health News:STAAR Surgical Completes Common Stock Offering 2Health News:STAAR Surgical Completes Common Stock Offering 3Health News:BioArts International Clones 9-11 Hero Dog - Owner to Receive Five Cloned Puppies June 17 in Los Angeles 2Health News:BioArts International Clones 9-11 Hero Dog - Owner to Receive Five Cloned Puppies June 17 in Los Angeles 3Health News:2009 ISSSEEM Conference to Have Deepak Chopra Discuss Bridging Science and Spirit 2Health News:2009 ISSSEEM Conference to Have Deepak Chopra Discuss Bridging Science and Spirit 3Health News:Bariatric Advantage High Protein Meal Replacement Clinical Study Presented at European Congress on Obesity 2Health News:Windows 7 Compatible Remote Desktop Software Released (Beta 4) 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: